Controlled clinical trials and cross-sectional studies with plasma histamine measurements and histamine receptor antagonists: solving the problem of preoperative H1- + H2-prophylaxis by asking new questions?
The problem of a preoperative histamine H1- + H2 - prophylaxis was tackled by a group of new studies including randomized controlled clinical trials and cross-sectional studies with plasma histamine measurements and administration of H1- + H2 - antagonists to a control group. The first study demonstrated serial histamine release in the induction of anaesthesia up to 4 times in a single patient. Basal plasma histamine levels in resting subjects fell below 100 pg/ml during the time necessary for preparation of the surgical patient. Hence, spikes of elevated plasma histamine concentrations corresponded to histamine release. Although this histamine release very often was less than 1 ng/ml plasma histamine, it created systemic reactions after atracurium. The cut-off point of 1 ng/ml for such anaphylactoid reactions does no longer exist, also lower plasma levels are of patho-physiological significance. The clinical signs of histamine release in the induction of anaesthesia vary from drug to drug. Sometimes tachycardia and hypertension produce the highest likelihood ratio, sometimes tachy- and bradycardia, but no changes in blood pressure as in the case of atracurium. It is concluded that the reasons why histamine release in anaesthesia and surgery is so much underreported and under-estimated include the present paradigms about plasma histamine levels and the "classical picture" of histamine release. Both are no longer valid and need a re-assessment.
Lorenz
W
W
Institute of Theoretical Surgery and Surgical Clinic, Centre of Operative Medicine I, Philipps, University of Marburg/Lahn, FRG.
Sitter
H
H
Stinner
B
B
Duda
D
D
Kapp
B
B
Gstrein
B
B
Dietz
W
W
Doenicke
A
A
Dick
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000758:Anesthesia; D001279:Atracurium / Q000009:adverse effects; D002927:Cimetidine / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D004115:Dimethindene / Q000627:therapeutic use; D005260:Female; D006439:Hemodynamics; D006632:Histamine / Q000097:blood*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006636:Histamine Release; D006801:Humans; D008297:Male; D008875:Middle Aged; D011097:Polygeline / Q000009:adverse effects; D011292:Premedication; D011899:Ranitidine / Q000627:therapeutic use
D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D001279:Atracurium; D004115:Dimethindene; D002927:Cimetidine; D006632:Histamine; D011899:Ranitidine; D011097:Polygeline